FrancophonIA/ELRC3.0 huggingface dataset:
English: The combination of efavirenz, emtricitabine and tenofovir disoproxil has been studied in 460 patients either as the fixed-dose combination tablet Atripla (study AI266073) or as the component products (study GS-01-934).
Croatian: Kombinacija efavirenza, emtricitabina i tenofovirdizoproksila ispitivana je u 460 bolesnika koji su primali tabletu Atriple s kombinacijom fiksnih doza (ispitivanje AI266073) ili lijekove s pojedinačnom komponentom (ispitivanje GS-01-934).
English: Immune Reactivation Syndrome: In HIV infected patients with severe immune deficiency at the time of initiation of CART, an inflammatory reaction to asymptomatic or residual opportunistic infections may arise.
Croatian: Sindrom imunološke reaktivacije: U bolesnika inficiranih HIV-om s teškom imunodeficijencijom u vrijeme početka CART-a može nastati upalna reakcija na asimptomatske ili rezidualne oportunističke infekcije.
English: Efavirenz non-competitively inhibits HIV-1 reverse transcriptase (RT) and does not significantly inhibit human immunodeficiency virus-2 (HIV-2) RT or cellular deoxyribonucleic acid (DNA) polymerases (α, β, γ, and δ).
Croatian: Efavirenz je nekompetitivni inhibitor reverzne transkriptaze virusa HIV-1 (RT) i ne inhibira značajno virus humane imunodeficijencije 2 (HIV-2) RT ili stanične polimeraze (α, β, γ i δ) deoksiribonukleinske kiseline (DNK).
English: Please refer to the Summary of Product Characteristics for the individual components for additional information regarding in vivo resistance with these medicinal products.
Croatian: U sažetku opisa svojstava lijeka potražite pojedinačne komponente lijeka za dodatne informacije o in vivo rezistenciji za ove lijekove.
English: There is a potential for reduction or increase in the plasma concentrations of phenytoin, phenobarbital and other anticonvulsants that are substrates of CYP isozymes with efavirenz.
Croatian: Postoji potencijal za smanjenje ili povećanje koncentracija plazme fenitoina, fenobarbitala i drugih antikonvulziva koji su supstrati CYP izozima kada se primjenjuju zajedno s efavirenzom.
English: No dose recommendation can be made for the use of Atripla with carbamazepine.
Croatian: Ne može se dati preporuka doze za primjenu Atriple s karbamazepinom.
English: When efavirenz was given with ritonavir 500 mg or 600 mg twice daily, the combination was not well tolerated (for example, dizziness, nausea, paraesthesia and elevated liver enzymes occurred).
Croatian: dozi 500 mg ili 600 mg dva puta dnevno, bolesnici nisu dobro podnosili tu kombinaciju (na primjer, dolazilo je do omaglica, mučnina, parastezije i povećanja vrijednosti enzima jetre).
English: Ethinyloestradiol:
Croatian: etinilestradiol:
English: Administration of efavirenz capsules with a high fat meal increased the mean AUC and Cmax of efavirenz by 28% and 79%, respectively, compared to administration in a fasted state.
Croatian: Primjena kapsula efavirenza uz obrok s velikom količinom masnoće povećala je srednju vrijednost AUC i vrijednost Cmax efavirenza za 28%, odnosno 79%, u usporedbi s davanjem natašte.
English: Pregnancies have occurred in women taking efavirenz, a component of Atripla, while using a contraceptive implant, although it has not been established that the efavirenz therapy caused the contraceptive to fail.
Croatian: U žena koje su uzimale efavirenz koji je jedna od djelatnih tvari Atriple, a istodobno su koristile i kontracepcijski implantat zabilježeni su slučajevi trudnoća, iako nije ustanovljeno da je terapija efavirenzom uzrokovala neučinkovitost kontraceptiva.
English: There were insufficient data to determine whether moderate or severe hepatic impairment (Child-Pugh-Turcotte Class B or C) affects efavirenz pharmacokinetics.
Croatian: Nema dovoljno dostupnih podataka za utvrđivanje utječe li umjereno ili teško oštećenje funkcije jetre (stadij B ili C Child-Pugh-Turcotte) na farmakokinetiku efavirenza.
English: The most frequently reported adverse reactions considered possibly or probably related to Atripla among patients treated up to 48 weeks in study AI266073 were psychiatric disorders (16%), nervous system disorders (13%), and gastrointestinal disorders (7%).
Croatian: Najčešće zabilježene nuspojave u bolesnika koji su liječeni do 48 tjedana u ispitivanju AI266073 za koje se smatra da su moguće ili vjerojatno povezane s Atriplom bile su psihijatrijski poremećaji (16%), poremećaji živčanog sustava (13%) i poremećaji probavnog sustava (7%).
English: • Genotypic resistance to efavirenz, predominantly the K103N mutation, developed in virus from 13/19 (68%) patients in the efavirenz + emtricitabine + tenofovir disoproxil group and in virus from 21/29 (72%) patients in the efavirenz + lamivudine/zidovudine group.
Croatian: • Genotipska rezistencija na efavirenz, pretežno mutacija K103N, razvila se kod virusa u 13/19 (68%) bolesnika iz skupine efavirenz + emtricitabin + tenofovirdizoproksil te kod virusa u 21/29 (72%) bolesnika u skupini efavirenz + lamivudin/zidovudin.
English: Patients with a prior history of psychiatric disorders appear to be at greater risk of serious psychiatric adverse reactions.
Croatian: Čini se da u bolesnika s povijesti bolesti psihijatrijskih poremećaja postoji veći rizik od ozbiljnih psihijatrijskih nuspojava.
English: Two subjects with confirmed virologic rebound developed NNRTI resistance-associated substitutions to efavirenz including K103N, V106V/I/M and Y188Y/C reverse transcriptase substitutions at week 240 (96 weeks on Atripla) and week 204 (60 weeks on Atripla).
Croatian: U dva ispitanika s potvrđenim ponovnim povratom virusnog opterećenja nastale su supstitucije povezane s rezistencijom na efavirenz (NNRTI) uključujući K103N, V106V/I/M i Y188Y/C supstitucije reverzne transkriptaze u 240. tjednu (96 tjedana na Atripli) i 204. tjednu (60 tjedana na Atripli).
English: Some examples include: - aminoglycosides, vancomycin (medicines for bacterial infections) - foscarnet, ganciclovir, cidofovir (medicines for viral infections) - amphotericin B, pentamidine (medicines for fungal infections) - interleukin-2 (to treat cancer) - non-steroidal anti-inflammatory drugs (NSAIDs, to relieve bone or muscle pains)
Croatian: Neki primjeri: - aminoglikozidi, vankomicin (lijekovi za bakterijske infekcije) - foskarnet, ganciklovir, cidofovir (lijekovi za virusne infekcije) - amfotericin B, pentamidin (lijekovi za gljivične infekcije) - interleukin-2 (za liječenje raka) - nesteroidne antiinflamatorne (protuupalne) lijekove (NSAIL, za ublažavanje boli u kostima ili mišićima)
English: Efavirenz: Non-clinical safety pharmacology studies on efavirenz reveal no special hazard for humans.
Croatian: Efavirenz: Neklinička ispitivanja sigurnosti efavirenza ne ukazuju na poseban rizik za ljude.
English: Table 2: Adverse reactions associated with Atripla listed by the component(s) of Atripla to which the adverse reactions are attributable
Croatian: Tablica 2: Nuspojave povezane s Atriplom navedene prema komponenti/komponentama Atriple kojima se nuspojave pripisuju
English: No dose adjustment is recommended.
Croatian: Nema preporučenih prilagodbi doziranja.
English: Patients at risk of renal impairment (such as patients with baseline renal risk factors, advanced HIV disease, or patients receiving concomitant nephrotoxic medications) are at increased risk of experiencing incomplete recovery of renal function despite tenofovir disoproxil discontinuation (see section 4.4).
Croatian: Bolesnici s rizikom od oštećenja funkcije bubrega (kao što su bolesnici s početnim bubrežnim čimbenicima rizika, uznapredovalom HIV bolešću ili bolesnici koji istodobno primaju nefrotoksične lijekove) pod povećanim su rizikom od nepotpunog oporavka funkcije bubrega usprkos prekidu terapije tenofovirdizoproksilom (vidjeti dio 4.4).
English: In some patients with advanced liver disease or cirrhosis, stopping treatment is not recommended as this may lead to worsening of your hepatitis, which may be life-threatening.
Croatian: U nekih se bolesnika s uznapredovalom bolešću jetre ili cirozom jetre ne preporučuje prekid liječenja, jer to može dovesti do pogoršanja hepatitisa, što može biti opasno po život.
English: - Other medicines used for HIV infection: The following protease inhibitors: darunavir, indinavir, lopinavir/ritonavir, ritonavir, or ritonavir boosted atazanavir or saquinavir.
Croatian: Drugi lijekovi za liječenje infekcije HIV-om: Sljedeći inhibitori proteaze: darunavir, indinavir, lopinavir/ritonavir, ritonavir ili atazanavir ojačan ritonavirom ili sakvinavir.
English: Compounds that are substrates of these enzymes may have decreased plasma concentrations when co-administered with efavirenz.
Croatian: Spojevi koji su supstrati ovih enzima mogu imati smanjene koncentracije u plazmi kada se primjenjuju istodobno s efavirenzom.
English: Clarithromycin:
Croatian: klaritromicin:
English: Currently available data indicate a trend that in patients on a PI-based antiretroviral regimen the switch to Atripla may lead to a reduction of the response to the therapy (see section 5.1).
Croatian: Trenutno raspoloživi podaci ukazuju na sljedeći trend: u bolesnika koji se liječe režimom antiretrovirusne terapije na osnovi inhibitora proteaze prelazak na Atriplu može dovesti do smanjenog odgovora na terapiju (vidjeti dio 5.1).
English: This loss is due to significant decreases in elbasvir/grazoprevir plasma concentrations caused by CYP3A4 or P-gp induction.
Croatian: Taj učinak posljedica je značajnih smanjenja koncentracija elbasvira/grazoprevira u plazmi zbog indukcije CYP3A4 ili P-gp-a.
English: (CYP3A4 or P-gp induction - effect on grazoprevir)
Croatian: (indukcija CYP3A4 ili P-gp-a - učinak na grazoprevir)
English: Animal studies do not indicate harmful effects of efavirenz, emtricitabine or tenofovir disoproxil on fertility.
Croatian: Ispitivanja na životinjama ne ukazuju na štetan učinak efavirenza, emtricitabina ili tenofovirdizoproksila na plodnost.
English: The degree of renal impairment was defined according to baseline creatinine clearance (normal renal function when creatinine clearance > 80 ml/min; mild impairment with creatinine clearance=50 to 79 ml/min; moderate impairment with creatinine clearance=30 to 49 ml/min and severe impairment with creatinine clearance=10 to 29 ml/min).
Croatian: Stupanj oštećenja funkcije bubrega definiran je prema početnom klirensu kreatinina (normalna funkcija bubrega kada je klirens kreatinina > 80 ml/min; blago oštećenje uz klirens kreatinina = 50 do 79 ml/min; umjereno oštećenje uz klirens kreatinina = 30 do 49 ml/min i teško oštećenje uz klirens kreatinina = 10 do 29 ml/min).
English: The following pack sizes are available: outer cartons containing 1 bottle of 30 film-coated tablets and 90 (3 bottles of 30) film-coated tablets.
Croatian: Dostupne su sljedeće veličine pakiranja: kutije s 1 bocom od 30 filmom obloženih tableta i 90 (3 boce po 30) filmom obloženih tableta.
English: No data are available on the safety and efficacy of Atripla in combination with other antiretroviral agents.
Croatian: Nema dostupnih podataka o sigurnosti i djelotvornosti Atriple u kombinaciji s drugim antiretrovirusnim lijekovima.
English: Nervous system symptoms
Croatian: Simptomi vezani uz živčani sustavi
English: It is indicated for the treatment of human immunodeficiency virus-1 (HIV-1) infection in adults aged 18 years and over with virologic suppression to HIV-1 RNA levels of < 50 copies/ml on their current combination antiretroviral therapy for more than three months.
Croatian: Indicirana je za liječenje odraslih osoba u dobi od 18 godina i više, koje su inficirane humanim virusom imunodeficijencije-1 (HIV-1), s virološkom supresijom razina HIV-1 RNA na < 50 kopija/ml na trenutnoj kombiniranoj antiretrovirusnoj terapiji tijekom više od tri mjeseca.
English: Patients should be advised to seek medical advice if they experience joint aches and pain, joint stiffness or difficulty in movement.
Croatian: Bolesnike treba uputiti da se obrate liječniku ako osjete bolove u zglobovima, ukočenost zglobova ili poteškoće pri kretanju.
English: In a 3-month drug interaction study, no significant differences in MPA pharmacokinetic parameters were found between subjects receiving efavirenz-containing antiretroviral therapy and subjects receiving no antiretroviral therapy.
Croatian: Tromjesečno ispitivanje interakcije lijekova nije pokazalo značajne razlike u parametrima farmakokinetike MPA između ispitanika koji su primali antiretrovirusnu terapiju s efavirenzom i ispitanika koji nisu primali antiretrovirusnu terapiju.
English: • softening of the bones (with bone pain and sometimes resulting in fractures) which may occur due to damage to the kidney tubule cells
Croatian: • omekšavanje kostiju (uz bolove u kostima i ponekad posljedične prijelome) do koje može doći uslijed oštećenja stanica bubrežnih kanalića
English: Elderly: Atripla has not been studied in patients over the age of 65.
Croatian: Starije osobe: Atripla se nije ispitivala u bolesnika starijih od 65 godina.
English: Emtricitabine and tenofovir disoproxil: A large amount of data on pregnant women (more than 1000 pregnancy outcomes) indicates no malformations or foetal/neonatal toxicity associated with emtricitabine and tenofovir disoproxil.
Croatian: Emtricitabin i tenofovirdizoproksil: Opsežni podaci (više od 1000 trudnoća) ukazuju da emtricitabin i tenofovirdizoproksil ne uzrokuju malformacije i da nemaju feto/neonatalni toksični učinak.
English: The in vitro studies suggest that CYP3A4 and CYP2B6 are the major isozymes responsible for efavirenz metabolism and that it inhibits CYP isozymes 2C9, 2C19, and 3A4.
Croatian: Ispitivanja in vitro ukazuju da su CYP3A4 i CYP2B6 glavni izozimi odgovorni za metabolizam efavirenza te da oni inhibiraju CYP izozime 2C9, 2C19 i 3A4.
English: There have been occasional post-marketing reports of contraceptive failure with etonogestrel in efavirenz-exposed patients.
Croatian: Iz razdoblja nakon stavljanja lijeka u promet postoje povremena izvješća o kontracepcijskom neuspjehu s etonogestrelom u bolesnika koji su bili izloženi efavirenzu.
English: Based on the concentration-QTc relationship, the mean QTc prolongation and its upper bound 90% confidence interval are 8.7 ms and 11.3 ms in subjects with CYP2B6*6/*6 genotype following the administration of 600 mg daily dose for 14 days
Croatian: Na temelju odnosa između koncentracije i QTc-a, srednja vrijednost produljenja QTc-a i gornja granica 90%-tnog intervala pouzdanosti iznose 8,7 ms i 11,3 ms u ispitanika s genotipom CYP2B6*6/*6 nakon primjene dnevne doze od 600 mg tijekom 14 dana (vidjeti dio 4.5).
English: Skin and subcutaneous tissue disorders: Very common rash (moderate-severe, 11.6%, all grades, 18%)3
Croatian: Poremećaji kože i potkožnog tkiva: Vrlo često osip (umjeren do težak, 11,6%, svi stupnjevi,
English: The potential for cross-resistance between efavirenz and PIs is low because of the different enzyme targets involved.
Croatian: Potencijal za križnu rezistenciju između efavirenza i inhibitora proteaze nizak je jer su uključeni drukčiji ciljni enzimi.
English: Blood and lymphatic system disorders: Common neutropenia
Croatian: Poremećaji krvi i limfnog sustava: Često neutropenija
English: Individual tolerability and virological response should be considered when making the dose adjustment (see section 5.2).
Croatian: Prilikom podešavanja doze nužno je uzeti u obzir pojedinačnu toleranciju i virološki odgovor (vidjeti dio 5.2).
English: The K65R mutation can also be selected by abacavir or didanosine and results in reduced susceptibility to these agents plus lamivudine, emtricitabine and tenofovir.
Croatian: Mutacija K65R može se također izdvojiti s abakavirom ili didanozinom, a rezultira smanjenom osjetljivošću na te lijekove te na lamivudin, emtricitabin i tenofovir.
English: Clinically significant interactions are not expected since vigabatrin and gabapentin are exclusively eliminated unchanged in the urine and are unlikely to compete for the same metabolic enzymes and elimination pathways as efavirenz.
Croatian: Ne očekuju se klinički značajne interakcije jer se vigabatrin i gabapentin eliminiraju nepromijenjeni isključivo u mokraći i nije vjerojatno da bi se natjecali za metabolitičke enzime i puteve eliminacije efavirenza.
English: fluoroquinolones, imidazole and triazole antifungal agents, - certain non-sedating antihistamines (terfenadine, astemizole), - cisapride, - flecainide, - certain antimalarials, - methadone (see sections 4.4, 4.5 and 5.1).
Croatian: antimikotici derivati imidazola i triazola - određeni nesedacijski antihistaminici (terfenadin, astemizol) - cisaprid - flekainid - određeni antimalarici - metadon (vidjeti dijelove 4.4, 4.5 i 5.1).
English: There is no specific antidote for overdose with efavirenz.
Croatian: Ne postoji specifični antidot u slučaju predoziranja efavirenzom.
English: Common diarrhoea, vomiting, abdominal pain, nausea elevated amylase including elevated pancreatic amylase, elevated serum lipase, vomiting, abdominal pain, dyspepsia abdominal pain, abdominal distension, flatulence
Croatian: Često proljev, povraćanje, bolovi u trbuhu, mučnina povišena amilaza uključujući povišenu amilazu gušterače, povišena serumska lipaza, povraćanje, bolovi u trbuhu, dispepsija bolovi u trbuhu, distenzija trbuha, flatulencija
English: In HIV infected patients with severe immune deficiency at the time of institution of CART, an inflammatory reaction to asymptomatic or residual opportunistic pathogens may arise and cause serious clinical conditions, or aggravation of symptoms.
Croatian: U bolesnika inficiranih HIV-om s teškom imunodeficijencijom u vrijeme uvođenja CART-a može doći do upalne reakcije na asimptomatske ili rezidualne oportunističke patogene koja može uzrokovati ozbiljna klinička stanja ili pogoršanje simptoma.
English: Efavirenz+lamivudine/zid ovudine (N=243)
Croatian: efavirenz+lamivudin/ zidovudin (N=243)
English: Women of childbearing potential should undergo pregnancy testing before initiation of Atripla.
Croatian: Žene reproduktivne dobi trebaju prije početka terapije Atriplom obaviti testiranje trudnoće.
English: Rash: In clinical trials of efavirenz, rashes were usually mild-to-moderate maculopapular skin eruptions that occurred within the first two weeks of initiating therapy with efavirenz.
Croatian: Osip: U kliničkim ispitivanjima efavirenza kod osipa se uglavnom radilo o blagim do umjerenim kožnim erupcijama koje su se pojavile unutar prva dva tjedna od početka terapije efavirenzom.
English: In a drug interaction study, carbamazepine plasma concentrations were decreased when carbamazepine was co-administered with efavirenz (see section 4.5).
Croatian: U ispitivanju interakcija među lijekovima, koncentracije karbamazepina u plazmi smanjile su se kada je karbamazepin primjenjivan istodobno s efavirenzom (vidjeti dio 4.5).
English: The adverse reactions from clinical study and post-marketing experience with Atripla and the individual components of Atripla in antiretroviral combination therapy are listed in Table 2 below by body system organ class, frequency and the component(s) of Atripla to which the adverse reactions are attributable.
Croatian: Nuspojave iz kliničkih ispitivanja i iskustva nakon stavljanja lijeka u promet s Atriplom i pojedinačnim komponentama Atriple u kombiniranoj antiretrovirusnoj terapiji navedene su u Tablici 2 u nastavku, prema klasifikaciji organskih sustava, učestalosti i komponenti/komponentama Atriple kojima se nuspojave pripisuju.
English: If your doctor decides to stop one of the components of Atripla, you may be given efavirenz, emtricitabine and/or tenofovir disoproxil separately or with other medicines for the treatment of your HIV infection.
Croatian: Ako Vaš liječnik odluči da je potrebno prekinuti uzimanje neke od komponenti Atriple, možda ćete dobiti odvojeno efavirenz, emtricitabin i/ili tenofovirdizoproksilfumarat ili u kombinaciji s drugim lijekovima za liječenje HIV infekcije.
English: As Atripla contains efavirenz, emtricitabine and tenofovir disoproxil, any interactions that have been identified with these agents individually may occur with Atripla.
Croatian: Obzirom da Atripla sadrži efavirenz, emtricitabin i tenofovirdizoproksil, sve interakcije koje su utvrđene u zasebnoj primjeni tih lijekova mogu se pojaviti i s Atriplom.
English: Posaconazole:
Croatian: posakonazol:
English: Clinically significant interactions have not been found and would not be expected since the NRTIs are metabolised via a different route than efavirenz and would be unlikely to compete for the same metabolic enzymes and elimination pathways.
Croatian: Nisu ustanovljene klinički značajne interakcije niti se one očekuju jer se lijekovi klase NRTI metaboliziraju drukčijim putem od efavirenza i nije vjerojatno da bi se natjecali za iste metabolitičke enzime i putove eliminacije.
English: Administration of activated charcoal may be used to aid removal of unabsorbed efavirenz.
Croatian: Kao pomoć u eliminaciji neapsorbiranog efavirenza može se koristiti aktivni ugljen.
English: Co-administration of tenofovir disoproxil and didanosine at a dose of 400 mg daily has been associated with a significant decrease in CD4 cell count, possibly due to an intracellular interaction increasing phosphorylated (i.e. active) didanosine.
Croatian: Istodobna primjena tenofovirdizoproksila i didanozina u dozi od 400 mg dnevno povezana je sa značajnim smanjenjem broja CD4 stanica, čemu je mogući uzrok unutarstanična interakcija koja povećava količinu fosforiliniranog (tj. aktivnog) didanozina.
English: Also, Atripla should not be taken with any other medicines that contain efavirenz (unless recommended by your doctor), emtricitabine, tenofovir disoproxil, tenofovir alafenamide, or lamivudine or adefovir dipivoxil.
Croatian: Također, Atripla se ne smije uzimati s drugim lijekovima koji sadržavaju efavirenz (osim ako Vam je to preporučio liječnik), emtricitabin, tenofovirdizoproksil, tenofoviralafenamid kao i lamivudin ili adefovirdipivoksil.
English: Dose adjustment: If Atripla is co-administered with rifampicin to patients weighing 50 kg or more, an additional 200 mg/day (800 mg total) of efavirenz may be considered (see section 4.5).
Croatian: Prilagođavanje doze: Ako se Atripla primjenjuje istodobno s rifampicinom u bolesnika tjelesne težine 50 kg ili više, može se uzeti u obzir davanje dodatnih 200 mg efavirenza dnevno (ukupno 800 mg) (vidjeti dio 4.5).
English: A third subject had pre-existing NNRTI resistance-associated substitutions to efavirenz and the M184V reverse transcriptase resistance-associated substitution to emtricitabine at entry into the Atripla extension phase and experienced a suboptimal virologic response, and developed K65K/R, S68N and K70K/E NRTI resistance-associated substitutions at week 180 (36 weeks on Atripla).
Croatian: Treći je ispitanik već imao supstitucije povezane s rezistencijom na efavirenz (NNRTI) i M184V supstituciju reverzne transkriptaze povezanu s rezistencijom na emtricitabin kod uključenja u proširenu fazu ispitivanja Atriple i suboptimalni virološki odaziv te je razvio K65K/R, S68N i K70K/E NRTI supstitucije povezane s rezistencijom u 180. tjednu (36 tjedana na Atripli).
English: Co-administration with herbal preparations containing St. John's wort (Hypericum perforatum) due to the risk of decreased plasma concentrations and reduced clinical effects of efavirenz (see section 4.5).
Croatian: Istodobna primjena s biljnim pripravcima koji sadržavaju gospinu travu (Hypericum perforatum) zbog rizika smanjenih koncentracija u plazmi i smanjenih kliničkih učinaka efavirenza (vidjeti dio 4.5).
English: If you notice any of these symptoms please inform your doctor.
Croatian: Ako opazite bilo koji od tih simptoma, obavijestite liječnika.
English: A decreased dosage of 250 mg didanosine co-administered with tenofovir disoproxil therapy has been associated with reports of high rates of virologic failure within several tested combinations.
Croatian: Terapija sa smanjenom dozom didanozina od 250 mg koja se primjenjuje zajedno s tenofovirdizoproksilom u nekoliko je ispitivanih kombinacija povezana s izvješćima o visokim stopama virološkog neuspjeha.